NASDAQ: ARCT |
| Healthcare / Biotechnology / USA |
16.14 | +0.1200 | +0.75% | Vol 1.33M | 1Y Perf -53.32% |
Jun 24th, 2022 16:00 DELAYED |
BID | 15.11 | ASK | 16.08 | ||
Open | 16.43 | Previous Close | 16.02 | ||
Pre-Market | - | After-Market | 15.84 | ||
- - | -0.30 -1.86% |
Target Price | 47.44 | Analyst Rating | Hold 2.78 | |
Potential % | 193.93 | Finscreener Ranking | ☆ 34.53 | |
Insiders Trans % 3/6/12 mo. | -/-100/-100 | Value Ranking | ★ 39.91 | |
Insiders Value % 3/6/12 mo. | -/-100/-100 | Growth Ranking | ★ 36.31 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 8.33 | Earnings Rating | Strong Sell | |
Market Cap | 426.39M | Earnings Date | 8th Aug 2022 | |
Alpha | 0.03 | Standard Deviation | 0.32 | |
Beta | 2.79 |
Today's Price Range 15.0316.58 | 52W Range 11.7065.00 | 5 Year PE Ratio Range -7.10-2.80 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | 19.82% | ||
1 Month | -5.78% | ||
3 Months | -40.62% | ||
6 Months | -59.59% | ||
1 Year | -53.32% | ||
3 Years | 64.86% | ||
5 Years | 105.87% | ||
10 Years | -77.91% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -51.62 | |||
ROE last 12 Months | -73.88 | |||
ROA (5Y Avg) | -14.66 | |||
ROA last 12 Months | -48.21 | |||
ROC (5Y Avg) | -41.58 | |||
ROC last 12 Months | -58.18 | |||
Return on invested Capital Q | -18.36 | |||
Return on invested Capital Y | -12.23 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 2.40 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-1.80 | ||||
1.93 | ||||
22.99 | ||||
- | ||||
-2.40 | ||||
-5.36 | ||||
1.93 | ||||
6.99 | ||||
105.39M | ||||
Forward PE | 6.13 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
3.00 | ||||
3.00 | ||||
0.19 | ||||
0.37 | ||||
-68.70 | ||||
Leverage Ratio | 1.70 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
-1 264.20 | ||||
-1 257.00 | ||||
-354.20 | ||||
-84.18 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
15.48M | ||||
0.59 | ||||
-13.02 | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | -1.29 | -1.94 | -50.39 |
Q04 2021 | -1.77 | -1.47 | 16.95 |
Q03 2021 | -1.40 | -2.05 | -46.43 |
Q02 2021 | -1.99 | -2.07 | -4.02 |
Q01 2021 | -1.16 | -2.15 | -85.34 |
Q04 2020 | -0.90 | -1.25 | -38.89 |
Q03 2020 | -0.47 | -0.92 | -95.74 |
Q02 2020 | -0.53 | -0.55 | -3.77 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -1.84 | -52.07 | Negative |
9/2022 QR | -1.65 | -135.71 | Negative |
12/2022 FY | -6.66 | -45.10 | Negative |
12/2023 FY | 2.00 | -52.72 | Negative |
Next Report Date | 8th Aug 2022 |
Estimated EPS Next Report | -1.84 |
Estimates Count | 4 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 1.33M |
Shares Outstanding | 26.42K |
Shares Float | 17.04M |
Trades Count | 13.53K |
Dollar Volume | 21.25M |
Avg. Volume | 1.01M |
Avg. Weekly Volume | 1.51M |
Avg. Monthly Volume | 813.42K |
Avg. Quarterly Volume | 711.21K |
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock closed at 16.14 per share at the end of the most recent trading day (a 0.75% change compared to the prior day closing price) with a volume of 1.33M shares and market capitalization of 426.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 88 people. Arcturus Therapeutics Holdings Inc. CEO is Joseph E. Payne.
The one-year performance of Arcturus Therapeutics Holdings Inc. stock is -53.32%, while year-to-date (YTD) performance is -56.39%. ARCT stock has a five-year performance of 105.87%. Its 52-week range is between 11.7 and 65, which gives ARCT stock a 52-week price range ratio of 8.33%
Arcturus Therapeutics Holdings Inc. currently has a PE ratio of -1.80, a price-to-book (PB) ratio of 1.93, a price-to-sale (PS) ratio of 22.99, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -48.21%, a ROC of -58.18% and a ROE of -73.88%. The company’s profit margin is -84.18%, its EBITDA margin is -1 257.00%, and its revenue ttm is $15.48 Million , which makes it $0.59 revenue per share.
Of the last four earnings reports from Arcturus Therapeutics Holdings Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.84 for the next earnings report. Arcturus Therapeutics Holdings Inc.’s next earnings report date is 08th Aug 2022.
The consensus rating of Wall Street analysts for Arcturus Therapeutics Holdings Inc. is Hold (2.78), with a target price of $47.44, which is +193.93% compared to the current price. The earnings rating for Arcturus Therapeutics Holdings Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Arcturus Therapeutics Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Arcturus Therapeutics Holdings Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 31.04, ATR14 : 1.95, CCI20 : -18.11, Chaikin Money Flow : 0.09, MACD : -1.11, Money Flow Index : 64.46, ROC : -17.40, RSI : 48.17, STOCH (14,3) : 49.78, STOCH RSI : 1.00, UO : 56.65, Williams %R : -50.22), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Arcturus Therapeutics Holdings Inc. in the last 12-months were: Padmanabh Chivukula (Sold 58 100 shares of value $2 571 008 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Hold | Moderate Buy | Moderate Buy |
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-2020.
CEO: Joseph E. Payne
Telephone: +1 858 900-2660
Address: 10628 Science Center Drive, San Diego 92121, CA, US
Number of employees: 88
Wed, 25 May 2022 08:40 GMT Arcturus Therapeutics (ARCT) Gets a Sell Rating from Goldman Sachs
- TipRanks. All rights reserved.Wed, 20 Apr 2022 16:05 GMT Arcturus Therapeutics (ARCT) Receives a Hold from H.C. Wainwright
- TipRanks. All rights reserved.Thu, 03 Mar 2022 10:22 GMT Arcturus Therapeutics (ARCT) Receives a Sell from Robert W. Baird
- TipRanks. All rights reserved.Wed, 26 Jan 2022 12:46 GMT Arcturus Therapeutics (ARCT) Gets a Hold Rating from H.C. Wainwright
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.